Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.15
+$0.03 · +2.68%
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Latest quote
$1.15
+$0.03 · +2.68%
After-hours
$1.15
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Day range
Current $1.15
52-week range
Current $1.15
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
53
Mixed
Risk
66
High Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Day range
Current $1.15
52-week range
Current $1.15
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.44M USD | 2.24M USD | 1.57M USD | 833.21K USD | 126.49K USD |
| Selling, general, and administrative | 8.1M USD | 9.64M USD | 600.19K USD | 20.94K USD | 11.64K USD |
| Operating expenses | 10.54M USD | 12.24M USD | 3.94M USD | 854.15K USD | 138.13K USD |
| Interest income | 125.64K USD | 48K USD | — | — | — |
| Interest expense | — | −4.34M USD | 1.64M USD | — | — |
| Depreciation and amortization | — | 4.34M USD | — | 854.15K USD | 138.13K USD |
| Operating income | −10.54M USD | −12.24M USD | −3.94M USD | −854.15K USD | −138.13K USD |
| Net income | −10.41M USD | −16.53M USD | −13.07M USD | −854.15K USD | −138.13K USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.00
247.83% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
